InvestorsHub Logo
Followers 7
Posts 582
Boards Moderated 0
Alias Born 08/25/2012

Re: buckysherm post# 29

Wednesday, 06/29/2022 3:24:45 PM

Wednesday, June 29, 2022 3:24:45 PM

Post# of 70
I just double down on Bavarian
COPENHAGEN, Denmark, June 28, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Medicines Agency (EMA) has granted access to its priority medicines (PRIME) scheme for MVA-BN® RSV in active immunization for the prevention of lower respiratory tract disease (LRTD) caused by Respiratory Syncytial Virus (RSV) in adults ≥60 years of age. There are no approved vaccines for RSV, and access to PRIME has been granted upon an assessment that the available clinical data overall show the potential of MVA-BN-RSV to address the unmet medical need in the proposed target population.

* (((A $6 billion dollar market))) and no competition. The over 60 was the targeted patient for the drug.